TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03188614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Description: The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluid resuscitation
Description: The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
Study: NCT02444585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: Intended to prevent periprosthetic loss of bone mineral density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Intended to prevent periprosthetic loss of bone mineral density
Study: NCT02416869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Dexamethasone submucosal
Description: Patients receive 4mg of submucosal Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8mg Dexamethasone submucosal
Description: Patients receive 8mg of submucosal Dexamethasone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Dexamethasone preoperative
Description: Patients receive 4mg of Dexamethasone preoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4mg Dexamethasone postoperative
Description: Patients receive 4mg of Dexamethasone postoperatively
Study: NCT06528600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hymovis ONE
Description: Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
Study: NCT03902938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodesign Otologic graft
Description: Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autograft temporalis fascia
Description: Patient's mastoid cavity will be covered with covered with autograft.
Study: NCT06146309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (2mg/0.05ml)
Description: Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
Study: NCT03134378

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole Sodium 20mg
Description: Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 20mg
Description: Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Twice daily
Study: NCT06528600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc
Description: Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
Study: NCT03106233

Intervention type: PROCEDURE
Intervention: LTP flap
Description: A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
Study: NCT03134378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 Mg
Description: Twice daily
Study: NCT02916992

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan of the thorax
Description: A low dose CT scan of the thorax (2mSv) wil be performed once.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan of the thorax
Description: A low dose CT scan of the thorax (2mSv) wil be performed once.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample for FLCN mutation analyses
Description: A venous punction in order to withdraw 16ml blood is undertaken once.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample for FLCN mutation analyses
Description: A venous punction in order to withdraw 16ml blood is undertaken once.
Study: NCT05586737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 gram rituximab twice with two weeks interval
Study: NCT04575935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Undergo laparotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery
Description: Undergo MIS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00861926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventolin
Description: Ventolin : salbutamol sulfate 100µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclometasone /formoterol
Description: BDP 100µg/FF 6µg, 1 inhalation bid
Study: NCT00004203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT00000257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 10% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 10% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 20% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 20% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 40% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 40% N2O
Study: NCT04089956

Intervention type: OTHER
Intervention: No interventation
Description: A retrospective cohort Observational study with no intervention

Intervention type: OTHER
Intervention: No interventation
Description: A retrospective cohort Observational study with no intervention
Study: NCT02371850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm patch first, then Aveva patch
Description: This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
Study: NCT00550160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine plus Artesunate co-administration
Description: Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus Artesunate co-administration
Description: Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.
Study: NCT05642546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo
Study: NCT01033773

Intervention type: DRUG
Group type: OTHER
Intervention: Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin
Description: Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes survival skills self-management education
Description: Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
Study: NCT03693716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Anterior Stabilization
Description: All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
Study: NCT00867490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan+HCTZ - Phase 1
Description: 4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren+HCTZ - Phase 2
Description: Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren+HCTZ+amlodipine - Phase 3
Description: The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
Study: NCT01154608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No enzyme therapy
Description: Current enzyme therapy of the patient is stopped during 7 days
Study: NCT04285060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung GEMS-H
Description: Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
Study: NCT01739426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repair w/LigaSure
Description: Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
Study: NCT01759927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity coaching
Description: After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
Study: NCT02505256

Intervention type: OTHER
Intervention: No intervention
Study: NCT00332904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
Study: NCT02945657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM36 topical ointment, 1%
Description: Twice daily application for 28 consecutive days
Study: NCT00502840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1g iv on days 1 and 15
Study: NCT03240926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Loop Band
Description: Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
Study: NCT03375385

Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine/ propofol
Description: The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).

Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine/ propofol
Description: The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).

Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine/ propofol
Description: The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).

Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine/ propofol
Description: The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
Study: NCT03488199

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Acculink ™
Description: Carotid Artery Revascularization using Stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGuardTM™
Description: Carotid Artery Revascularization using Stents
Study: NCT02937805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisturizing vaginal and vulvar sea buckthorn oil cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing vaginal and vulvar cream
Study: NCT01591005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endarterectomy
Description: carotid endarterectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: endarterectomy
Description: carotid endarterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid stenting
Description: percutaneous transluminal angioplasty and stenting

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: carotid stenting
Description: percutaneous transluminal angioplasty and stenting
Study: NCT00833092

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill supplementation for 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium
Description: 300 milligrams daily for 8 weeks
Study: NCT03700047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAL1704
Description: new dermal filler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAL1704
Description: new dermal filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma
Description: hyaluronic acid
Study: NCT01621932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct anterior approach with capsulectomy
Description: Direct anterior approach with capsulectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct anterior approach without capsulectomy
Description: Direct anterior approach without capsulectomy
Study: NCT02586805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930 - 300mg/2wk
Description: 300 mg DX-2930 administered every 2 weeks by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930 - 300mg/4wk
Description: 300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930 - 150mg/4wk
Description: 150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every 2 weeks by subcutaneous injection.
Study: NCT03182764

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00087438

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Study: NCT02086227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon for Injection (Fresenius Kabi USA)
Description: Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon for Injection (Bedford Laboratories)
Description: Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
Study: NCT01843010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: Parecoxib 40mg will be intravenously infused.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 5ml will be intravenously infused.
Study: NCT02906553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03314506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
Study: NCT02734173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT450r-ABT267-ABT333 +/- Ribavirin
Description: 12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT450r-ABT267-ABT333 +/- Ribavirin
Description: 12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT450r-ABT267-ABT333 +/- Ribavirin
Description: 12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
Study: NCT03744455

Intervention type: BIOLOGICAL
Intervention: Axillary Plexus
Description: Axillary plexus anesthesia technique for hand surgery

Intervention type: BIOLOGICAL
Intervention: Axillary Plexus
Description: Axillary plexus anesthesia technique for hand surgery
Study: NCT00316264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab, palivizumab
Description: Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palivizumab, motavizumab
Description: Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Study: NCT02494570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Sirolimus
Description: Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
Study: NCT02036320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
Study: NCT04203914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Tablets
Description: Add-on 25mg once daily